01. October 2018

The occurrence of protein aggregation during bioprocessing steps such as purification, formulation and fill-finish, impacts yield and production costs, and must be controlled throughout themanufacturing process. Understanding aggregation mechanisms and developing mitigating strategies are imperative to ensure the clinical efficacy of the protein drug product and to reduce costs. Thiscommentary reflects on recent progress made in the field of monoclonal antibody (mAb) aggregation with...

25. July 2018

Dry Powder Inhaler (DPI) could offer a propellant-free, easy-to-use powder form ensuring better stability than liquid dosae forms. Therefore the development of traditional carrier-based and carrier-free new generation systems is a determinative factor in the field of DPI formulation. The purpose of our research work was to combine these two systems, utilizing their beneficial properties to produce a novel pulmonary drug delivery system containing ciprofloxacin hydrochloride (CIP). Co-spray...

16. October 2017

Excipients, once considered as far less important than the active pharmaceutical ingredient (API) in formulated medicines, today are receiving significantly more attention from both manufacturers and regulators. Many excipient technologies are no longer considered as simply inactive ingredients.

26. October 2016

Abstract The multiparticulate drug product concept covering micropellets, pellets, and mini-tablets is presented as a highly feasible approach to present convenient and patient friendly medication for the geriatric population. Improved swallowability and optimized administration regimen going along with defined drug dosage are achievable. Extemporaneous preparation of medicines from standard medication can be avoided going along with improved patient safety. With one multiparticulate pellet,...

26. January 2016

05. January 2016